Last updated on June 2018

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)


Brief description of study

To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis

Detailed Study Description

To evaluate the effect of peramanel for 48 weeks on progression of disease in subjects with ALS, as measured by ALS Functional Rating Scale-Revised (ALSFRS-R)

Clinical Study Identifier: NCT03019419

Contact Investigators or Research Sites near you

Start Over

Makoto Urushitani, MD,PhD

Shiga University of Medical Science Hospital
Shiga, Japan
  Connect »